Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Xiaohong Pu"'
Autor:
Jing Cai, Jun Chen, Qing Ye, Yudong Qiu, Hongyan Wu, Yao Fu, Xiangshan Fan, Xin Yang, Shen Yue, Xiaohong Pu
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 12, Iss 3, Pp 1-14 (2021)
Cell Death and Disease, Vol 12, Iss 3, Pp 1-14 (2021)
Chromosomal translocations involving fibroblast growth factor receptor 2 (FGFR2) gene at the breakpoints are common genetic lesions in intrahepatic cholangiocarcinoma (ICC) and the resultant fusion protein products have emerged as promising druggable
Publikováno v:
Pathology, research and practice. 216(12)
Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (RCC) is a rare subtype of RCC with gene fusion involving ALK at 2p23. It was first included in the renal tumor classification system by WorldHealth organization (WHO) as a distinct eme
Autor:
Jing Cai, Xiaohong Pu, Yixing Yao, Steven Y. Cheng, Bo'ang Han, Hengqing Liao, Chen Liu, Longyan Shen, Tingting Yu, Shen Yue
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 8, Pp 1-14 (2020)
Cell Death and Disease, Vol 11, Iss 8, Pp 1-14 (2020)
Reversible phosphorylation of Suppressor of fused (Sufu) is essential for Sonic Hedgehog (Shh) signal transduction. Sufu is stabilized under dual phosphorylation of protein kinase A (PKA) and glycogen synthase kinase 3β (GSK3β). Its phosphorylation
Publikováno v:
Pathology, research and practice. 216(4)
As an increasing number of gene alterations have been discovered in intrahepatic cholangiocarcinoma (ICC), molecular targets are promising for the diagnosis and treatment of distinct subpopulations carrying unique molecular signatures. C-MET amplific
Publikováno v:
Pathology - Research and Practice. 216:153116
Background As more and more molecular markers have been identified in Intrahepatic Cholangiocarcinoma (ICC), target treatments are promising all around the world. However, geographical and ethnic variations in the ICC epidemiology suggest different g
Publikováno v:
Pathology - Research and Practice. 211(6):421-425
It has been proven that chromosome 17 centromere (CEP17) amplification causes misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ hybridization (FISH) results, precluding anti-HER2-based therapy in some patients with